drugset / Trial / NCT00427856
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.
Timeline
- Start
- 2007-03
- Primary completion
- 2009-02
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obatoclax | Small molecule | 40 mg | Other |
| Subject | Obatoclax | Small molecule | 60 mg | Other |
| Subject | Rituximab | Monoclonal antibody | — | — |